OakChart

Mannkind Corp

MNKDHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

4.19-0.04 (-0.95%)
2026-11-12 01:53 CET
Market cap
1,347.67 USD m
Revenue, TTM
413.37 USD m
Net income, TTM
-74.82 USD m
Free cash flow, TTM
-78.65 USD m
EPS diluted, TTM
-0.24
P/E
-
Compare

Price

MNKD against its 20, 50 and 200-day averages
2050200missearnings
3.003.504.004.5010.2M20.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MNKDclose 4.1920-day 3.5250-day 3.57200-day 3.664.19

35.6% under the 52-week high of 6.51 on 8 Jan 2026. 52-week low 2.23 on 27 Mar 2026. Last 15 sessions, 42.4% high to low

Volume 0.81× normal · the line is the 50-bar volume average

Profile

MNKD
52-week range, 46% of the way up
2.236.51

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

IndexRUT
Employees592
IPOJul 28, 2004
Beta1.06
ATR, 14d0.21
Rel volume0.81
Short float8.54%
Insider own4.53%
Inst own53.74%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.35B
Enterprise Value1.69B
Income-74.82M
Sales413.37M
Book/sh-0.12
Cash/sh0.30
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees592
IPOJul 28, 2004

Ratios

P/E-
Forward P/E85.70
PEG1.65
P/S3.26
P/B-
P/C13.95
P/FCF-
EV/EBITDA93.80
EV/Sales4.08
Quick Ratio1.77
Current Ratio2.22
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.24
EPS next Y0.05
EPS next Q0.01
EPS this Y-955.56%
EPS next Y128.57%
EPS next 5Y51.83%
EPS past 3/5Y- -
Sales past 3/5Y51.80% 39.89%
EPS Y/Y TTM-344.30%
Sales Y/Y TTM31.74%
EPS Q/Q-383.20%
Sales Q/Q24.04%
EarningsNov 05 AMC
EPS/Sales Surpr.-6.71% -4.82%

Ownership

Insider Own4.53%
Insider Trans-1.41%
Inst Own53.74%
Inst Trans-3.92%
ROA-12.29%
ROE-
ROIC-19.43%
Gross Margin71.44%
Oper. Margin-1.95%
Profit Margin-18.10%
SMA2019.05%
SMA5017.52%
SMA20014.33%
Trades-

Technical

Shs Outstand321.63M
Shs Float307.06M
Short Float8.54%
Short Ratio6.46
Short Interest26.22M
52W High6.51 -35.64%
52W Low2.23 87.89%
Volatility7.47% 5.51%
ATR (14)0.21
RSI (14)69.58
Beta1.06
Rel Volume0.81
Avg Volume4.06M
Volume3,282,995

Performance

Perf Week6.62%
Perf Month37.38%
Perf Quarter12.33%
Perf Half Y30.53%
Perf YTD-26.10%
Perf Year-20.19%
Perf 3Y22.16%
Perf 5Y-15.52%
Perf 10Y26.97%
Recom1.22
Target Price8.33
Prev Close4.23
Price4.19
Change %-0.95%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 19, 2026InitiatedCChardan Capital MarketsBuy$10+138.7%
Feb 27, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform$3.50-16.5%
Nov 24, 2025InitiatedTTruistBuy
Nov 13, 2025InitiatedLLeerink PartnersOutperform$7+67.1%
Oct 20, 2025InitiatedWWells FargoOverweight$10+138.7%
Oct 10, 2025InitiatedLLeerink PartnersOutperform$9+114.8%
Jul 16, 2025ResumedHH.C. WainwrightBuy$9+114.8%
Apr 10, 2025InitiatedMMizuhoOutperform$12+186.4%
Feb 10, 2025InitiatedWWedbushOutperform$11+162.5%
Dec 20, 2024InitiatedWWells FargoOverweight$9+114.8%

Peers

Mkt cap
TickerCompanyMkt cap
INSMInsmed Inc26.49B
LQDALiquidia Corp4.94B
XERSXeris Biopharma Holdings Inc3.02B
SVRASavara Inc1.10B
UTHRUnited Therapeutics Corp25.37B
AVLNAvalyn Pharma Inc1.40B
TNDMTandem Diabetes Care Inc1.31B
AQSTAquestive Therapeutics Inc449.96M
NVONovo Nordisk ADR137.48B
LLYLilly(Eli) & Co1352.12B

Insider trading

latest 14 of 37
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Binder Steven B.DirectorSep 25 '26Sale3.2939,051128,478713,258Sep 28 08:26 PM
STEVEN BINDERDirectorSep 25 '26Proposed Sale3.2939,051128,478Sep 25 04:17 PM
Binder Steven B.DirectorSep 10 '26Sale3.8133,558127,856752,309Sep 14 08:00 PM
STEVEN BINDERDirectorSep 10 '26Proposed Sale3.9433,558132,219Sep 10 04:43 PM
Binder Steven B.DirectorAug 07 '26Sale4.0639,051158,547785,867Aug 10 08:44 PM
STEVEN BINDERDirectorAug 07 '26Proposed Sale3.8939,051151,908Aug 07 04:39 PM
Tross Stuart AChief People & Workpl OfficerJul 15 '26Option Exercise0.0093,79001,123,950Jul 17 09:45 PM
Castagna MichaelChief Executive OfficerJul 15 '26Option Exercise0.00350,26002,796,979Jul 17 09:44 PM
Singh Sanjay REVP Technical OperationsJul 15 '26Option Exercise0.0070,5500525,761Jul 17 09:44 PM
Thomson DavidEVP Genl Counsel & SecretaryJul 15 '26Option Exercise0.0093,7900920,089Jul 17 09:43 PM
Thomson DavidEVP Genl Counsel & SecretaryJul 17 '26Sale4.0524,10997,641797,554Jul 17 09:43 PM
Binder Steven B.DirectorJul 15 '26Option Exercise0.0093,7900901,798Jul 17 09:42 PM
Binder Steven B.DirectorJul 17 '26Sale4.0652,485213,089824,918Jul 17 09:42 PM
DAVID THOMSONOfficerJul 17 '26Proposed Sale4.0424,10997,400Jul 17 04:21 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • MannKind to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • MannKind Edges Past EPS Consensus, But A Revenue Miss And An Implied Furoscix Shortfall Temper The ReadyFlow Launch (Earnings Whispers)
  • MannKind: Q3 Earnings Snapshot (Associated Press)
  • MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • MannKind's Furosix Ramp And Pediatric Afrezza Uptake Face First Real Test After Catalyst Sweep (Earnings Whispers)
  • MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 (GlobeNewswire)
  • MannKind to Participate in the Chardan Healthcare Conference (GlobeNewswire) +5.63%
  • MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) (GlobeNewswire)
  • MannKind Expands Into Weight Loss With Rose Pharma Deal Heres What Investors Are Watching (Stocktwits) -5.29%
  • MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management (GlobeNewswire)
  • MannKind to Present at Upcoming Investor Conferences (GlobeNewswire)
  • MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ... (GuruFocus.com) -5.12%
  • MannKind: Q2 Earnings Snapshot (Associated Press)
  • MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.070-0.066-0.070101.87107.039
2026Q22026-08-05-0.060-0.008-0.062109.37108.088
2026Q12026-05-06-0.0500.000-0.05490.17105.388
2025Q42026-02-26-0.0500.017-0.052111.9697.589
2025Q32025-11-050.0300.0190.02682.1380.248
2025Q22025-08-060.0000.0500.00276.5378.798
2025Q12025-05-080.0400.0420.04178.3576.024
2024Q42025-02-260.0300.0360.02676.7874.377
2024Q32024-11-070.0400.0300.04170.0873.324
2024Q22024-08-07-0.0100.008-0.00772.3964.815
2024Q12024-05-080.0400.0260.03366.2660.555
2023Q42024-02-270.0000.0030.00458.0053.506
2023Q32023-11-070.010-0.0170.00651.2550.736
2023Q22023-08-07-0.020-0.038-0.02048.6142.955
2023Q12023-05-09-0.040-0.050-0.03740.6337.405
2022Q42023-02-23-0.070-0.051-0.06836.0635.506

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.270-0.264-0.26563.0462.07
2020FY-0.260-0.180-0.25765.1462.88
2021FY-0.320-0.269-0.32575.4480.01
2022FY-0.340-0.322-0.34099.7799.59
2023FY-0.040-0.045-0.045199194
2024FY0.1000.1060.097285.5281.03
2025FY0.0200.1710.020348.97342.39
2026FY--0.171--434.47
2027FY-0.049--517.58
2028FY-0.070--519.2
2029FY-0.231--601.44
2030FY-0.370--664.8

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06934132.87123.53141.54
2026Q4S2026-11-05902132.86122146.9
2026Q4S2026-10-20902132.86122146.9
2026Q4S2026-10-16907132.86122146.9
2026Q4S2026-10-12807133.64123.53146.9
2026Q4S2026-10-09816134.84125.85146.9
2026Q4S2026-09-01807133.64123.5146.9
2026Q4S2026-08-13807133.64123.5146.9
2026Q4S2026-08-06807133.6123.5146.9
2026Q4S2026-08-03821142.51124167.5
2026Q4S2026-07-29820143.79127.47167.5
2026Q4S2026-07-23820143.18127.47162.6
2026Q4S2026-07-21820143.3127.47162.6
2026Q4S2026-07-06880143.3127.47162.6

Estimate history

EPS, annual-1.13-0.603-0.265-0.257-0.325-0.34-0.0450.0970.019-0.2399
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0410.0260.0410.0020.026-0.052-0.054-0.062-0.073
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual11.74527.85963.03865.14475.44299.77198.962285.504348.966413.37
Period201720182019202020212022202320242025TTM
Sales, quarterly70.07976.77678.35476.52782.13111.95590.171109.374101.87
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual119.053187.03211.788242.117251.478263.793270.034302.96307.833321.634
Period201720182019202020212022202320242025MRQ
Shares, quarterly275.775302.96303.919306.332307.027307.833308.907309.912321.634
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue413.37348.97285.50198.9699.7775.4465.1463.0427.86
Cost of Goods Sold Incl. D&A118.0691.9376.6062.7757.5038.8624.6427.9820.48
Gross Profit295.31257.03208.90136.1942.2736.5940.5035.067.38
Selling, General and Administrative Excl. Other303.37200.79140.22125.60111.1989.7365.2981.5788.45
Research and Development77.1866.3545.8931.2819.7212.316.256.908.74
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-8.0756.2468.6810.59-68.92-53.14-24.79-46.51-81.07
Interest Expense51.7038.0337.9825.1624.7716.589.4710.919.44
Unusual Expense14.7016.1021.990.170.9317.3115.39-3.530.76
Net Income Before Taxes-79.611.4130.52-10.38-87.40-80.93-57.46-51.90-86.73
Income Taxes-4.79-4.462.931.560.000.00-0.220.000.24
Consolidated Net Income-74.825.8627.59-11.94-87.40-80.93-57.24-51.90-86.97
Net Income From Continuing Operations-74.825.8627.59-11.94-87.40-80.93-57.24-51.90-86.97
Net Income-74.825.8627.59-11.94-87.40-80.93-57.24-51.90-86.97
EPS (Recurring)-0.200.050.15-0.04-0.34-0.28-0.21-0.28-0.60
EPS (Basic, Before Extraordinaries)-0.240.020.10-0.04-0.34-0.32-0.26-0.27-0.60
EPS (Diluted)-0.240.020.10-0.04-0.34-0.32-0.26-0.27-0.60
EBITDA17.9868.5277.6516.39-62.63-49.89-21.81-43.73-79.37
Non-Operating Income (Expense)-5.14-0.7021.814.367.226.10-7.821.984.53
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense23.7819.1116.8713.9413.4512.204.756.205.42
Price To Earnings Ratio--91.47------
Price To Sales Ratio3.025.106.394.8913.5814.4410.694.005.48
Gross Margin71.4473.6673.1768.4542.3748.4962.1755.6226.49
Operating Margin-1.9516.1224.065.32-69.08-70.44-38.05-73.78-291.01
Net Margin-18.101.689.66-6.00-87.60-107.27-87.87-82.34-312.20
Shares Outstanding321.63307.83302.96270.03263.79251.48242.12211.79187.03
Market Capitalization1,347.671,360.541,773.25981.251,387.041,097.99728.04266.27169.17

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue101.87109.3790.17111.9582.1376.5378.3576.78
Cost of Goods Sold Incl. D&A28.6733.9121.8433.6520.2020.5717.5219.60
Gross Profit73.2075.4768.3378.3161.9355.9660.8457.17
Selling, General and Administrative Excl. Other75.7776.3071.3279.9843.1545.3036.0435.11
Research and Development14.3618.0017.2327.5914.0613.6811.0211.14
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.57-0.84-2.98-1.6718.7810.6624.8022.06
Interest Expense10.5814.8212.4313.877.336.1910.637.48
Unusual Expense0.004.993.696.026.410.000.0013.39
Net Income Before Taxes-23.17-19.14-16.37-20.937.780.9413.628.45
Income Taxes0.05-0.110.25-4.98-0.200.270.461.02
Consolidated Net Income-23.22-19.03-16.62-15.957.990.6713.167.42
Net Income From Continuing Operations-23.22-19.03-16.62-15.957.990.6713.167.42
Net Income-23.22-19.03-16.62-15.957.990.6713.167.42
EPS (Recurring)-0.07-0.05-0.05-0.040.040.000.040.06
EPS (Basic, Before Extraordinaries)-0.07-0.06-0.05-0.050.030.000.040.03
EPS (Diluted)-0.07-0.06-0.05-0.050.030.000.040.03
EBITDA4.665.563.404.3621.5313.2327.4024.74
Non-Operating Income (Expense)-10.021.512.750.632.75-3.53-0.557.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.098.085.105.513.415.944.254.60
Price To Earnings Ratio--144.9760.1349.1337.5154.9791.47
Price To Sales Ratio3.023.352.094.995.333.865.426.55
Gross Margin71.8569.0075.7869.9575.4073.1277.6574.47
Operating Margin-2.53-0.76-3.31-1.4922.8613.9331.6528.74
Net Margin-22.80-17.40-18.43-14.259.720.8716.799.67
Shares Outstanding321.63309.91308.91307.83307.03306.33303.92302.96
Market Capitalization1,347.671,316.13754.851,741.091,647.671,136.711,527.061,773.25

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments171.35197.26295.10170.85204.1267.1650.2071.6848.35
Short Term Receivables39.0712.8015.4016.804.994.223.514.022.79
Inventories35.3127.8928.5521.777.154.974.163.602.66
Other Current Assets45.8530.3634.3525.483.483.122.892.563.01
Total Current Assets291.58268.31373.39234.90219.7479.4860.7681.8556.81
Net Property, Plant & Equipment94.2598.4788.9145.1336.6125.8726.7825.6026.92
Total Investments and Advances5.766.227.161.9656.620.000.000.000.00
Intangible Assets392.297.203.003.58-----
Other Assets8.3113.652.749.728.193.276.190.250.84
Total Assets792.18393.84475.20295.28321.16108.6193.72107.7084.58
Short Term Debt Incl. Current Port. of LT Debt49.2413.1231.9810.498.065.405.0312.9454.39
Accounts Payable9.036.799.5811.056.965.584.795.386.98
Income Tax Payable-0.051.56------
Other Current Liabilities112.7661.8761.0045.7633.3362.7355.8056.9226.23
Total Current Liabilities171.0381.84104.1267.3048.3573.7065.6275.2487.60
Long Term Debt424.14144.10350.39377.87380.61125.30123.6598.39111.28
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities248.03246.73266.85100.66101.5690.0294.98109.16100.43
Total Liabilities843.20472.66721.37545.82530.51289.03284.25282.79299.31
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-51.02-78.82-246.17-250.54-209.35-180.42-190.53-175.08-214.73
Total Shareholders Equity-51.02-78.82-246.17-250.54-209.35-180.42-190.53-175.08-214.73
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-51.02-78.82-246.17-250.54-209.35-180.42-190.53-175.08-214.73
Total Liabilities & Stockholders Equity792.18393.84475.20295.28321.16108.6193.72107.7084.58
Book Value Per Share-0.17-0.26-0.91-0.95-0.83-0.75-0.90-0.94-1.80
Tangible Book Value Per Share-1.44-0.28-0.92-0.96-0.83-0.75-0.90-0.94-1.80
Full-Time Employees592407414395349241233225250
Price to Book Ratio-36.51-8.45-3.90-5.83-5.25-4.20-1.43-1.13-0.97
Return on Assets0.996.35-3.10-28.36-37.66-56.58-51.53-90.47-122.45
Return on Invested Capital1.5742.26-11.45-68.64-47.25----
Quick Ratio1.502.943.313.174.401.010.861.040.62
Current Ratio1.703.283.593.494.541.080.931.090.65

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-74.825.8627.59-11.94-87.40-80.93-57.24-51.90-86.97
Depreciation24.2312.289.045.849.115.473.332.151.70
Other Funds (Non Cash)50.5450.9941.9625.3821.6531.4735.57-26.3710.86
Funds from Operations-5.0264.1778.5919.28-56.64-43.98-18.35-76.12-74.41
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-61.47-45.91-36.4714.63-24.05-17.73-9.78-12.3636.68
Cash from Operating Activities-66.4918.2542.1133.91-80.70-61.71-28.13-88.48-37.73
Capital Expenditures-12.16-4.57-9.69-42.44-7.59-11.47-0.80-2.56-0.35
Net Assets From Acquisitions-347.74-347.740.000.00-15.340.00-3.980.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.12
Purchase or Sale of Investments104.3257.5151.120.00-5.00-3.0020.00-19.980.00
Purchase of Investments-57.50-157.80-7.010.00-5.00-3.000.00-44.970.00
Sale Or Maturity of Investments161.82215.3158.130.000.000.0020.0024.990.00
Other Uses0.00-10.00-273.79-79.09-74.54-196.130.00-0.300.00
Other Sources0.000.00135.71119.55107.3459.060.000.000.00
Cash from Investing Activities-255.58-304.80-96.65-1.994.87-151.5415.22-22.84-0.23
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock50.390.000.006.7822.56-1.1334.759.1665.86
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock50.390.000.006.7822.56-1.1334.759.1665.86
Proceedsfrom Stock Options50.390.000.006.7822.24-0.6334.989.0465.86
Issuance or Reduction of Debt, Net205.99316.37-125.07138.36-1.09171.6814.8762.78-5.00
Change in Long Term Debt205.99316.37-125.07138.36-1.09171.6814.8769.700.00
Issuance of Long Term Debt242.73317.730.00145.950.00230.0014.87119.930.00
Reduction of Long Term Debt-36.75-1.36-125.07-7.59-1.09-58.320.00-50.230.00
Net Financing Active Other Cash Flow-20.41-1.27-11.80-8.34-0.0699.710.23-2.080.44
Other Financing Activities Uses-22.41-3.26-14.94-10.16-0.38-2.540.00-2.080.00
Cash from Financing Activities235.96315.10-136.87136.8021.41270.2749.8569.8661.29
Net Change in Cash-86.1128.55-191.40168.71-54.4257.0236.94-41.4623.33
Free Cash Flow-78.6513.6932.42-8.54-88.29-73.17-28.93-91.05-38.09
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-130.1156.30------
Deferred Taxes & Investment Tax Credit--4.970.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments96.61111.13133.86171.35260.04178.99
Short Term Receivables41.4343.7128.7439.0718.8828.04
Inventories48.4744.4249.1735.3126.9728.49
Other Current Assets53.9646.4639.4045.8552.9543.51
Total Current Assets240.48245.71251.16291.58358.84279.03
Net Property, Plant & Equipment96.7796.0193.8494.2593.9594.75
Total Investments and Advances0.750.750.755.7626.9722.98
Intangible Assets378.40383.56387.93392.297.057.10
Other Assets6.226.2810.728.317.847.84
Total Assets722.62732.30744.40792.18494.64411.70
Short Term Debt Incl. Current Port. of LT Debt13.0913.0812.8849.2448.9548.94
Accounts Payable14.3811.0416.149.037.2710.26
Other Current Liabilities81.05118.77105.53112.7652.9152.63
Total Current Liabilities108.52142.90134.56171.03109.13111.83
Long Term Debt422.44423.27423.79424.14177.00104.13
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities228.92233.33245.25248.03253.07250.78
Total Liabilities759.88799.50803.60843.20539.19466.74
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-37.27-67.20-59.20-51.02-44.55-55.04
Total Shareholders Equity-37.27-67.20-59.20-51.02-44.55-55.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-37.27-67.20-59.20-51.02-44.55-55.04
Total Liabilities & Stockholders Equity722.62732.30744.40792.18494.64411.70
Book Value Per Share-0.12-0.22-0.19-0.17-0.15-0.18
Tangible Book Value Per Share-1.29-1.45-1.45-1.44-0.17-0.20
Full-Time Employees---592--
Price to Book Ratio-36.16-22.23-14.78-39.07-29.89-19.39
Return on Assets-12.29-7.62-4.140.996.107.67
Return on Invested Capital-6.03-5.34-4.56-4.276.031.36
Quick Ratio1.771.411.501.503.042.24
Current Ratio2.221.721.871.703.292.50

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-23.22-19.03-16.62-15.957.990.67
Depreciation7.236.406.384.212.802.62
Other Funds (Non Cash)14.6213.799.5712.5613.5017.00
Funds from Operations-1.371.16-0.67-4.1424.2920.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-33.41-19.79-4.97-3.29-0.80-11.51
Cash from Operating Activities-34.79-18.63-5.64-7.4323.498.77
Capital Expenditures-3.21-5.08-1.88-1.99-1.12-1.12
Net Assets From Acquisitions0.000.000.00-347.740.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments2.9622.9920.6157.77-13.937.37
Purchase of Investments-33.480.00-10.30-13.72-55.95-44.02
Sale Or Maturity of Investments36.4322.9930.9171.5042.0251.40
Other Uses0.000.000.000.00-10.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.2517.9118.73-291.96-25.066.26
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock50.530.920.27-1.340.051.29
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock50.530.920.27-1.340.051.29
Proceedsfrom Stock Options50.530.920.27-1.340.051.29
Issuance or Reduction of Debt, Net-0.52-0.10-35.40242.0174.360.00
Change in Long Term Debt-0.52-0.10-35.40242.0174.360.00
Issuance of Long Term Debt0.00-0.100.10242.7375.000.00
Reduction of Long Term Debt-0.520.00-35.50-0.73-0.640.00
Net Financing Active Other Cash Flow-26.630.000.006.21-2.45-6.62
Other Financing Activities Uses-26.630.000.004.22-2.45-5.03
Cash from Financing Activities23.390.82-35.13246.8871.96-5.33
Net Change in Cash-11.650.10-22.05-52.5170.399.70
Free Cash Flow-37.99-23.71-7.52-9.4222.367.66
Price to Free Cash Flow--57.78127.2739.1541.29

Revenue breakdown

Afrezza2024: 64.04M 2025: 74.59M
Consolidation, Policy2025: -106.00K
Furoscix2025: 23.18M
License and Service2024: 100.84M 2025: 106.82M
Royalty2024: 102.34M 2025: 128.12M
V Go2024: 18.29M 2025: 16.37M
United States2024: 285.50M 2025: 348.97M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.54%26.2M307.1M4.21M
2026-10-158.30%25.5M307.0M4.52M
2026-09-308.52%26.2M307.0M4.48M
2026-09-159.58%29.4M306.9M4.46M
2026-08-318.65%26.6M306.9M4.68M
2026-08-149.32%28.6M306.8M5.17M
2026-07-319.10%27.9M306.5M5.83M
2026-07-159.57%28.2M294.5M5.72M
2026-06-308.89%26.2M294.5M5.47M
2026-06-1510.64%31.3M293.9M5.73M
2026-05-2910.30%30.3M294.5M6.09M
2026-05-159.98%29.4M294.5M6.66M
2026-04-3010.04%29.7M296.1M5.67M
2026-04-1510.00%29.6M295.9M5.85M
2026-03-319.98%29.5M295.2M5.90M
2026-03-137.69%22.7M295.2M5.18M
2026-02-278.68%25.6M295.2M4.53M
2026-02-138.91%26.2M294.2M3.46M
2026-01-308.79%26.2M298.4M3.74M
2026-01-159.15%27.3M298.4M3.68M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.503.304.103.7051.06671.009.000.986-0.0560.000
call1.003.103.303.1316.3341547.000.955-0.1810.000
call1.502.353.202.6522.0587.007.000.927-0.1920.000
call2.001.802.552.1314.1056.003.000.897-0.1890.001
call2.501.401.951.639.3556.002.000.861-0.1790.001
call3.000.801.751.2010.66417.001.000.814-0.1640.001
call3.500.301.350.989.0596.000.000.746-0.1400.001
call4.000.200.300.251.63848220.000.629-0.0890.001
call4.500.000.200.102.7076050.000.395-0.0860.001
call5.000.000.600.043.9073.000.000.309-0.1120.001
call5.500.000.750.004.8520.000.000.268-0.1300.001
call6.000.000.350.005.4120.000.000.244-0.1350.001
call6.500.002.150.006.3290.000.000.225-0.1540.001
call7.000.002.150.006.9340.000.000.212-0.1630.001
call8.000.000.350.007.7070.000.000.194-0.1680.001
put0.500.000.050.0519.9781.000.00-0.014-0.0560.000
put1.000.002.150.0023.5180.000.00-0.045-0.1810.000
put1.500.002.150.0017.0820.000.00-0.073-0.1920.000
put2.000.002.150.0413.00521.000.00-0.103-0.1890.001
put2.500.002.150.009.9840.000.00-0.139-0.1790.001
put3.000.002.150.087.5321.000.00-0.186-0.1630.001
put3.500.000.750.005.3940.000.00-0.254-0.1400.001
put4.000.000.650.003.3590.000.00-0.371-0.0880.001
put4.500.100.550.003.0630.000.00-0.605-0.0860.001
put5.000.351.400.817.34124.001.00-0.691-0.1110.001
put5.500.003.500.0020.7770.000.00-0.732-0.1290.001
put6.001.354.000.0016.9860.000.00-0.757-0.1420.001
put6.501.854.502.7013.4691.000.00-0.775-0.1530.001
put7.002.353.302.869.8484.007.00-0.788-0.1620.001
put8.003.404.903.7516.1980.002.00-0.806-0.1770.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-218-KCurrent report2026-08-21SEC
2026-08-21424B7SEC
2026-08-14SCHEDULE 13GSEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13GSEC
2026-07-248-KCurrent report2026-07-23SEC
2026-07-17144Filing for proposed sale of securities under Rule 144.SEC
2026-07-17144Filing for proposed sale of securities under Rule 144.SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-06-028-KCurrent report2026-05-29SEC
2026-05-288-KCurrent report2026-05-27SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900256.33K2
2026-0800158.55K1
2026-0700310.73K2
2026-060000
2026-050065.71K2
2026-040000
2026-03259.00K100
2026-020000
2026-0100297.55K1
2025-12002.07M5
2025-110094.45K1

Institutional holders

Manager% owned
BlackRock, Inc.10.40%
Rubric Capital Management LP5.83%
STATE STREET CORP5.24%
VANGUARD CAPITAL MANAGEMENT LLC4.26%
WELLINGTON MANAGEMENT GROUP LLP2.54%
GEODE CAPITAL MANAGEMENT, LLC2.50%
Frazier Life Sciences Management, L.P.2.14%
Deep Track Capital, LP1.94%
180 WEALTH ADVISORS, LLC1.55%
FMR LLC1.41%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.76%
iShares Russell 2000 ETF2.59%
Select Biotechnology Portfolio1.41%
VANGUARD EXTENDED MARKET INDEX FUND1.14%
Fidelity Small Cap Index Fund1.05%
iShares Russell 2000 Growth ETF0.92%
iShares Biotechnology ETF0.67%
VANGUARD RUSSELL 2000 INDEX FUND0.55%
Janus Henderson Small/Mid Cap Growth Alpha ETF0.53%

OakChart. MNKD. Cached 15 minutes.